Tissue Regeneration Systems (TRS) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology has been evaluated in several large animal studies with very promising long term results. We have completed all required bench and animal testing and, to date, filed two 510K submissions to the FDA. We recently received our initial 510K approval, clearing both our technology platform and our first product for commercialization in the United States. Approval of a second 510K is pending. Other submissions are in work. Once we obtain a "critical mass" of product approvals, TRS will become a commercial company, and we expect to generate meaningful revenues in the next two years.